How Foundayo (orforglipron) works, who it may be suitable for, and what we know so far.
What is it: Foundayo is a new oral medication that's recently been approved by the MHRA.
Availability: Foundayo isn't currently available for weight loss patients in the UK.
Enter your email address to get the latest updates on Foundayo in your inbox.
Thanks for signing up. We'll send you all the latest updates on Foundayo, straight to your inbox.
 "Woman's Torso in Warm Ambient Light")
Foundayo, which contains the active ingredient orforglipron, is a new, once-daily oral GLP-1 medicine being studied for weight loss and type 2 diabetes, with clinical trials, to date, showing promising results.1
Like semaglutide (Wegovy), it mimics the gut hormone GLP-1 to reduce appetite and help you feel fuller, but it’s designed as a tablet rather than an injection.
In the large ATTAIN-1 phase 3 clinical trial, which included over 3,000 adults with obesity or considered overweight, people taking the highest dose experienced an average weight loss of 12.4% (around 12 kg) over 72 weeks, compared with less than 1% with placebo.2
The results were broadly consistent across doses, and many people achieved substantial weight loss, with almost 6 in 10 losing at least 10% of their body weight, and around 4 in 10 losing 15% or more on the highest dose.2
Researchers also saw improvements in markers linked to heart health, including cholesterol, triglycerides, and blood pressure, as well as lower levels of inflammation.2 As with other GLP-1 medicines, side effects varied between individuals.
 "Consultation 2")
Foundayo has recently been approved by the MHRA and will soon be available on prescription in the UK.
Although it isn’t available in the UK yet, you don’t have to put your weight loss journey on pause. If you’re looking for structured, clinically-led support now, Numan’s Weight Loss Programme helps you build momentum with treatments that are already available and proven.
That includes tailored plans using licensed and approved weight loss medications alongside coaching to help you manage side effects, stay consistent, and keep your results moving in the right direction. If new treatment becomes available in the future, you’ll be in a stronger position to discuss next step with your clinician.
In the best, albeit limited, head-to-head data we have so far, orforglipron has shown greater reductions in both blood sugar and weight than oral semaglutide in people with type 2 diabetes. In Lilly’s 52-week ACHIEVE-3 trial (adults on metformin), the highest dose of orforglipron reduced HbA1c by ~2.2% vs ~1.4% with oral semaglutide, and people lost ~9.2% of body weight (about 8.9kg) vs ~5.3% (about 5kg) on oral semaglutide.3
Compared with injectable weight loss medicines, available data suggests a different efficacy profile. The leading injections (like Wegovy and Mounjaro) tend to deliver larger average weight loss in obesity studies, but one potential advantage of orfoglipron is that it’s a once-daily pill, which could make treatment easier for some people if it’s approved and widely available.5
 "flippedgeneralhealth")
1 Dutta D, Nagendra L, Anne B, Kumar M, Sharma M, Kamrul-Hasan ABM. Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis. Obes Sci Pract. 2024;10(2):e743.
2 Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial. Eli Lilly and Company. [accessed 20 Jan 2026] Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically
3 What to know about orforglipron: An investigational oral GLP-1. Lilly.com. 2025. [accessed 20 Jan 2026] Available from: https://www.lilly.com/news/stories/what-to-know-about-orforglipron
4 Lilly’s oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial. Lilly.com. 2025. [accessed 20 Jan 2026] Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head
Answer a few simple questions to get the treatment you need.
Updated:
 "01_AppPromo_Mob_01png")
 "01_AppPromo_Desktop_01")